---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005439"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:54:38.997082+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome

## Summary
- First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.
- Trial to evaluate safety, tolerability, PK and immunogenicity in healthy adults and Netherton patients.
- Initial data from the trial expected by end of 2025; no approved treatments currently exist for the disease.
- BCX17725 is BioCryst's first protein therapeutic to advance to the clinic.
- Netherton syndrome is an ultra-rare, life-threatening genetic disorder affecting skin, hair, and immune system.

## SEC filing metadata
- accession: 0001171843-24-005439
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/0001171843-24-005439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/f8k_100224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005439
- JSON: https://secwatch.observer/filing/0001171843-24-005439.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.